GlassScriptPhysician profile
Sheetal Wadera
NPI 1730419086
$3,783.75
in general payments reported to CMS, 2019-2025
15 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.61 · 2020: $19.46 · 2021: $54.59 · 2022: $2,594 · 2023: $193 · 2024: $501 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,050.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Albireo Pharma, INC. | $2,298.37 | 2022 | |
| Mirum Pharmaceuticals, INC. | $459.98 | 2023-2025 | Livmarli |
| Ipsen Biopharmaceuticals, INC | $386.19 | 2024-2025 | Bylvay |
| Genzyme Corporation | $160.83 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $116.91 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.13 | 2021-2022 | |
| Travere Therapeutics, INC. | $59.68 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $38.53 | 2024 | |
| Qol Medical, LLC | $36.06 | 2019-2021 | |
| Abbvie INC. | $28.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.39 | 2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $21.26 | 2022 | |
| Greenwich Biosciences, INC. | $19.46 | 2020 | |
| Pfizer INC. | $16.43 | 2021 | |
| Pharming Healthcare, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheetal Wadera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.